Sept 28 (Reuters) – A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc (GILD.O) HIV drugs, including two alleged “kingpins .” Gilead, which has been pursuing alleged counterfeiters in a civil lawsuit since …
Gilead widens battle against alleged counterfeit HIV drug ring Read More »
LONDON, Sept 30 (Reuters) – British pension funds with big losses in gilt market derivatives have sought emergency funds from the companies they manage money for as they race to dump assets to raise cash, industry sources said on Friday. Many pension funds were caught out during the surge in bond yields this week that …
UK pension funds ask corporates for cash after gilt blow-up -sources Read More »
Tesla gains on plans to raise production Major indexes set for third straight quarterly decline Nike slumps on margin warning, drags athletic gear makers Down 0.36%, S&P flat, Nasdaq up 0.32% Sept 30 (Reuters) – The Nasdaq index rose on Friday as Tesla gained on its plans to sharply increase production, even though resilient core …
Nasdaq boosted by Tesla, rate hike worries linger Read More »
AMSTERDAM, Sept 30 (Reuters) – Inflation in the Netherlands jumped in September to its highest in decades, driven by skyrocketing energy prices, the statistics agency (CBS) said on Friday. Consumer prices, harmonized to be comparable with inflation data from other European Union countries (HICP), rose to 17.1% this month after August’s jump to 13.7%. Energy …
Dutch inflation leaps to 17%, boosted by high energy prices Read More »
Sept 29 (Reuters) – Amylyx Pharmaceuticals Inc (AMLX.O) said on Thursday the US Food and Drug Administration approved its drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death, sending shares of the company up nearly 14 % in extended trading. The company added healthcare professionals can soon write prescriptions for …
S&P 500 index back at near two-year lows Airlines, cruises fall on cancellations due to Hurricane Ian CarMax slumps on missing second-quarter expectations Indexes down: Dow 1.54%, S&P 2.15%, Nasdaq 3.05% Sept 29 (Reuters) – Wall Street tumbled on Thursday on worries of a global economic downturn from aggressive central bank policy and fears that …
Wall Street nosedives on mounting economic growth concerns Read More »
Sept 29 (Reuters) – Saudi Arabia’s Savvy Games Group, owned by sovereign wealth fund PIF, will invest 142 billion riyals ($37.8 billion) in initiatives aimed at making the kingdom a global hub for gaming, state news agency SPA said on Thursday. The investments will include 70 billion riyals to take several minority stakes in companies …
Saudi wealth fund’s Savvy Games Group to invest $37.8 billion Read More »
Weekly jobless claims drop 16,000 to 193,000 Continuing claims decrease 29,000 to 1.347 million Second-quarter GDP contraction unrevised at 0.6% rate WASHINGTON, Sept 29 (Reuters) – The number of Americans filing new claims for unemployment benefits fell to a five-month low last week as the labor market remains resilient despite rising headwinds from the Federal …
US weekly jobless claims fall to five-month low; Q2 GDP unrevised Read More »
TOKYO, Sept 28 (Reuters) – Japan’s Shionogi & Co Ltd (4507.T) said on Wednesday its oral treatment for COVID-19 demonstrated a significant reduction in symptoms compared with a placebo in a Phase III trial in Asia. The drug, a protease inhibitor known as ensitrelvir, met its primary endpoint in a trial conducted among predominantly vaccinated …
Shionogi says COVID pill trial shows reduction in symptoms Read More »
Biogen, Eisai report landmark result for experimental drug Nearly all Alzheimer’s trials have failed previously Drugs from Roche and Eli Lilly target the same protein as Biogen, Eisai compound Shares of all four drugmakers soar on news LONDON, Sept 28 (Reuters) – The results of a key Alzheimer’s drug trial on Wednesday have reignited decades-old …
Analysis: Alzheimer’s drug trial breakthrough boost for Roche, Eli Lilly Read More »
/cloudfront-us-east-2.images.arcpublishing.com/reuters/667UKACI7FONBA7YTHN6I5JO3Q.jpg?w=1024&resize=1024%2C&ssl=1)